| Literature DB >> 30893598 |
David Sibon1, Tereza Coman2, Julien Rossignol2, Mathilde Lamarque1, Olivier Kosmider3, Elisa Bayard1, Guillemette Fouquet1, Rachel Rignault1, Selin Topçu1, Pierre Bonneau1, Florence Bernex4, Michael Dussiot1, Kathy Deroy5, Laetitia Laurent5, Jacques Callebert6, Jean-Marie Launay6, Sophie Georgin-Lavialle7, Geneviève Courtois1, Luc Maroteaux8, Cathy Vaillancourt5, Michaela Fontenay3, Olivier Hermine9, Francine Côté10.
Abstract
Tryptophan as the precursor of several active compounds, including kynurenine and serotonin, is critical for numerous important metabolic functions. Enhanced tryptophan metabolism toward the kynurenine pathway has been associated with myelodysplastic syndromes (MDSs), which are preleukemic clonal diseases characterized by dysplastic bone marrow and cytopenias. Here, we reveal a fundamental role for tryptophan metabolized along the serotonin pathway in normal erythropoiesis and in the physiopathology of MDS-related anemia. We identify, both in human and murine erythroid progenitors, a functional cell-autonomous serotonergic network with pro-survival and proliferative functions. In vivo studies demonstrate that pharmacological increase of serotonin levels using fluoxetine, a common antidepressant, has the potential to become an important therapeutic strategy in low-risk MDS anemia refractory to erythropoietin.Entities:
Keywords: SSRI; Tph1; anemia; erythropoiesis; myelodysplastic syndrome; serotonin
Mesh:
Substances:
Year: 2019 PMID: 30893598 DOI: 10.1016/j.celrep.2019.02.071
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423